Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
Prelude Therapeutics Incorporated (PRLD)
Company Research
Source: GlobeNewswire
- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789 monotherapy dose escalation - At doses studied to date, PRT3789 was generally well-tolerated with no dose-limiting toxicities or study drug-related serious adverse events - Company to host investor conference call and webcast on Friday, September 13, 2024 at 12:00 PM EST WILMINGTON, Del., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the first interim clinical data from its ongoing Phase 1 open-label, dose-escalation trial of PRT3789, a first-in-class SMARCA2 degrader, highly selective for SMARCA2 and designed to treat cancer patients with a SMARCA4 mutation. The data were presented at the European Society for Medical Oncology (ESMO) Congress 2024 in B
Show less
Read more
Impact Snapshot
Event Time:
PRLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRLD alerts
High impacting Prelude Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
PRLD
News
- Prelude Therapeutics Incorporated (NASDAQ: PRLD) was upgraded by analysts at HC Wainwright from a "hold" rating to a "strong-buy" rating.MarketBeat
- Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $7.00 price target on the stock.MarketBeat
- Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024GlobeNewswire
PRLD
Earnings
- 8/12/24 - In-Line
PRLD
Sec Filings
- 9/13/24 - Form 8-K
- 9/9/24 - Form 8-K
- 8/12/24 - Form 10-Q
- PRLD's page on the SEC website